Helix BioPharma Gives Update on L-DOS47 Phase II Study

- May 1st, 2019

Helix BioPharma announced the Trial Steering Committee reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.

Helix BioPharma (TSX:HBP) announced the Trial Steering Committee (TSC) reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.

As quoted in the press release:

No serious adverse events or dose limiting toxicities were observed. TSC recommended that Helix begin enrollment of patients into the second dosing cohort.

LDOS003 is a Phase II, open-label, randomized study of immunoconjugate L-DOS47 in combination with vinorelbine and cisplatin as compared to vinorelbine and cisplatin alone in patients with lung adenocarcinoma.

“We are very encouraged that the first dosing cohort of this L-DOS47 phase II study in combination with chemotherapy has been completed,” said Heman Chao, Helix’s Chief Executive Officer.  “We look forward to receiving more data as we advance the L-DOS47 development program.”

Click here to read the full press release.

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Leave a Reply